RxDoctor Payments Data

Teresa Farrugia, DO

Neurology · Massapequa, NYNPI 1861465155

Payments from drug & device makers

$14,900in general payments, 2019–2025

Across 793 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Eisai Inc.$2K
  • Biogen$915
  • UCB, Inc.$755
  • Teva Pharmaceuticals USA, Inc.$740
  • Takeda Pharmaceuticals U.S.A., Inc.$494
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$1891%
  • Food & beverage$14,43197%
  • Education$2792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)134$2,077
Eisai Inc.41$1,545
Biogen53$915
UCB, Inc.46$755
Teva Pharmaceuticals USA, Inc.22$740
Takeda Pharmaceuticals U.S.A., Inc.25$494
AstraZeneca25$470
Lundbeck LLC26$461
Amgen(2 entities)31$456
Amneal Pharmaceuticals LLC21$402
Supernus Pharmaceuticals, Inc.19$324
Novartis21$322
Upsher-smith Laboratories LLC16$299
Ipsen Biopharmaceuticals, Inc16$292
Pfizer15$277
Arbor Pharmaceuticals, Inc.16$259
Avanir Pharmaceuticals, Inc.11$231
Sanofi15$230
EMD Serono, Inc.16$229
Argenx US, Inc.9$201
Acorda Therapeutics, Inc11$189
Neurelis, Inc.11$189
Collegium Pharmaceutical, Inc.11$188
Biohaven Pharmaceuticals, Inc.9$186
Sunovion Pharmaceuticals Inc.12$169
Lilly USA, LLC11$163
Corium, LLC7$130
Axsome Therapeutics, Inc.5$127
Redhill Biopharma Inc.7$126
Biohaven Pharmaceutical Holding Company Ltd.6$124
SK Life Science, Inc.6$123
Bausch Health US, LLC6$120
Neurocrine Biosciences, Inc.5$114
E.r. Squibb & Sons, L.L.C.7$114
Bristol Myers Squibb6$113
GE HealthCare8$106
Harmony Biosciences LLC6$104
Sumitomo Pharma America, Inc.5$90
Amylyx Pharmaceuticals, Inc.2$90
Kyowa Kirin, Inc.5$88
Acadia Pharmaceuticals Inc5$87
Scilex Pharmaceuticals Inc.5$84
Tanabe Pharma America, Inc.4$68
Almatica Pharma LLC4$66
Mallinckrodt Enterprises LLC3$64
Merck3$61
Jazz Pharmaceuticals Inc.3$60
Neos Therapeutics, LP3$58
Vanda Pharmaceuticals Inc.3$53
Grifols USA, LLC2$50
Merz Pharmaceuticals, LLC2$45
Abbott2$43
Promius Pharma LLC3$43
Valinor Pharma, LLC2$42
Impel Pharmaceuticals Inc.2$41
Tris Pharma Inc2$40
Shire North American Group Inc2$39
Adlon Therapeutics L.p.2$35
Medtronic(2 entities)2$34
Otsuka America Pharmaceutical, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,900 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$399,074
Medicare patients
357
Services billed
24,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate64$86,471
OxycontinOxycodone Hcl41$53,431
Emgality PenGalcanezumab-Gnlm32$36,378
RytaryCarbidopa/Levodopa24$36,080
Nucynta ErTapentadol Hcl14$28,828
QuliptaAtogepant20$28,500
UbrelvyUbrogepant24$26,329
BotoxOnabotulinumtoxina15$20,540
Aimovig AutoinjectorErenumab-Aooe16$13,992
Oxtellar XrOxcarbazepine18$10,194
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine64$6,344
Oxycodone Hcl186$5,375
Memantine Hcl133$5,346
Lidocaine43$5,175
Lisdexamfetamine Dimesylate15$3,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$277$86,47164 claims
AbbVieQulipta, Ubrelvy, Botox$2,077$75,36959 claims
Amneal Pharmaceuticals LLCRytary$402$36,08024 claims
Collegium Pharmaceutical, Inc.Nucynta Er$188$28,82814 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$324$10,19418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →